Previous in vivo studies evaluated GPR4 inhibitors in myocardial infarction, arthritis, nociception, and angiogenesis mouse models and demonstrated that GPR4 inhibition reduced the disease severity when compared with vehicle control (Fukuda et al., 2016, Miltz et al., 2017). The gene discussed is GPR4; the disease is myocardial infarction.